Literature DB >> 6329091

Pharmacokinetics of sultamicillin in mice, rats, and dogs.

A R English, D Girard, S L Haskell.   

Abstract

The irreversible beta-lactamase inhibitor sulbactam has been combined chemically via ester linkages with ampicillin to form sultamicillin . Upon oral absorption, sultamicillin is completely hydrolyzed to equimolar proportions of sulbactam and ampicillin, thereby acting as an efficient mutual prodrug. In rats, sultamicillin delivered 2 to 2.5 times greater total bioavailability for ampicillin and sulbactam than when each was used individually. Actual plasma or serum concentrations (measured in micrograms per milliliter) of ampicillin and sulbactam produced by sultamicillin were generally equivalent in rats, mice, and beagle dogs. Further studies also indicated that the components of sultamicillin were widely distributed in the various tissues of rats. These findings suggest that sultamicillin might be an effective agent against a variety of infections produced by both beta-lactamase-resistant and beta-lactamase-susceptible microorganisms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329091      PMCID: PMC185595          DOI: 10.1128/AAC.25.5.599

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  A three-way crossover study to compare the pharmacokinetics and acceptability of sultamicillin at two dose levels with that of ampicillin.

Authors:  S Hartley; R Wise
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

3.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

Review 4.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  Pirbenicillin: pharmacokinetic parameters in mice.

Authors:  A R English; D Girard; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  6 in total
  9 in total

1.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  New sensitive bioassay for sulbactam in bovine tissues.

Authors:  G H Keeler; J P Stankewich; A E Girard; J J Rash
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 3.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 4.  Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.

Authors:  Valeria Ciaffaglione; Maria N Modica; Valeria Pittalà; Giuseppe Romeo; Loredana Salerno; Sebastiano Intagliata
Journal:  ChemMedChem       Date:  2021-09-07       Impact factor: 3.540

Review 5.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

6.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

7.  Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers.

Authors:  B Hampel; H Lode; G Bruckner; P Koeppe
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  A Comprehensive Study to Identify Major Metabolites of an Amoxicillin-Sulbactam Hybrid Molecule in Rats and Its Metabolic Pathway Using UPLC-Q-TOF-MS/MS.

Authors:  Fei-Ke Zhao; Ren-Bin Shi; Yu-Bin Sun; Shuang-Yun Yang; Liang-Zhu Chen; Bing-Hu Fang
Journal:  Metabolites       Date:  2022-07-18

9.  Pre-ischemic Treatment with Ampicillin Reduces Neuronal Damage in the Mouse Hippocampus and Neostriatum after Transient Forebrain Ischemia.

Authors:  Kyung-Eon Lee; Seul-Ki Kim; Kyung-Ok Cho; Seong Yun Kim
Journal:  Korean J Physiol Pharmacol       Date:  2008-12-31       Impact factor: 2.016

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.